Why the study?
Comorbid type 2 diabetes mellitus worsens the prognosis of cardiovascular diseases, and the prognostic value of asymmetric dimethylarginine (ADMA) for recurrent events in patients with acute myocardial infarction and type 2 diabetes was evaluated.
Does elevated asymmetric dimethylarginine (ADMA) predict recurrent acute myocardial infarction in patients with AMI and comorbid type 2 diabetes?
Cohort (n=140)
Yes
Does elevated asymmetric dimethylarginine (ADMA) predict recurrent acute myocardial infarction in patients with AMI and comorbid type 2 diabetes?
Effect estimate: AUC 0.726 (95% CI 0.588-0.838)
Absolute Event Rate: 27.14% vs 14%
Elevated ADMA levels on the first day of acute myocardial infarction serve as a predictor for recurrent myocardial infarction within 6 months, particularly in patients with comorbid type 2 diabetes.
No takes yet. Share an insight, caveat, or question.
D. А. Feldman (2021) conducted a cohort in Acute myocardial infarction with or without type 2 diabetes mellitus (n=140). Elevated asymmetric dimethylarginine (ADMA) levels vs. Lower ADMA levels / isolated acute myocardial infarction was evaluated on Recurrent acute myocardial infarction within 6 months (AUC 0.726, 95% CI 0.588-0.838).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: